Physician profile
Edward C Anderson
NPI 1326104910
$4,901.14
in general payments reported to CMS, 2019-2025
36 companies · $1,300 in 2025
The $1,300 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $597 · 2022: $267 · 2023: $998 · 2024: $1,739 · 2025: $1,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,037.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,053.27 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $579.72 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $525.92 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $482.58 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $338.84 | 2023-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $307.40 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $205.02 | 2022-2025 | Caplyta |
| Lundbeck LLC | $142.51 | 2022-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $125.82 | 2021-2024 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.02 | 2021-2024 | Xifaxan |
| Abbott Laboratories | $102.98 | 2023-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $101.36 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $86.93 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.14 | 2021-2025 | Jardiance |
| Verity Pharmaceuticals INC. | $65.71 | 2024-2025 | Tlando |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $64.89 | 2024-2025 | Abilify Maintena, Rexulti |
| Novartis Pharmaceuticals Corporation | $55.66 | 2023-2024 | |
| Kowa Pharmaceuticals America, INC. | $55.56 | 2023-2025 | Zoryve, Livalo, Seglentis |
| Glaxosmithkline, LLC. | $54.35 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $35.02 | 2025 | Verquvo |
| Xeris Pharmaceuticals, INC. | $33.27 | 2021-2023 | Gvoke Hypopen |
| Alkermes, INC. | $31.71 | 2021 | |
| Dexcom, INC. | $29.28 | 2021-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $28.32 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $22.44 | 2025 | Spravato |
| Nevro Corp. | $21.81 | 2024 | Senza |
| Sumitomo Pharma America, INC. | $20.78 | 2023 | Gemtesa |
| Axsome Therapeutics, INC. | $20.17 | 2024 | Auvelity |
| Optinose US, INC. | $19.44 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $19.33 | 2025 | |
| Corium, LLC | $16.18 | 2021 | |
| Viiv Healthcare Company | $14.86 | 2023 | Apretude |
| Almatica Pharma LLC | $13.23 | 2023 | Loreev Xr |
| Astellas Pharma US INC | $13.00 | 2023 | Veozah |
| Nestle Healthcare Nutrition INC. | $12.02 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.